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Abstract
Chronic orofacial pain is a symptom associated with a wide range of neuropathic, neurovascular, idiopathic, and
myofascial conditions that affect a significant proportion of the population. While the collective impact of the subset
of the orofacial pain disorders involving neurogenic and idiopathic mechanisms is substantial, some of these are
relatively uncommon. Hence, patients with these disorders can be vulnerable to misdiagnosis, sometimes for years,
increasing the symptom burden and delaying effective treatment. This manuscript first reviews the decision tree to
be followed in diagnosing any neuropathic pain condition, as well as the levels of evidence needed to make a
diagnosis with each of several levels of confidence: definite, probable, or possible. It then examines the clinical
literature related to the idiopathic and neurogenic conditions that can occasion chronic orofacial pain, including
burning mouth syndrome, trigeminal neuralgia, glossopharyngeal neuralgia, post-herpetic neuralgia, and atypical
odontalgia. Temporomandibular disorders also are examined as are other headache conditions, even though they
are not neurologic conditions, because they are common and can mimic symptoms of the latter disorders. For each
of these conditions, the paper reviews literature regarding incidence and prevalence, physiologic and other
contributing factors, diagnostic signs and symptoms, and empirical evidence regarding treatments. Finally, in order
to improve the quality and accuracy of clinical diagnosis, as well as the efficiency with which effective treatment is
initiated and delivered, criteria are offered that can be instrumental in making a differential diagnosis.
Keywords: Orofacial pain disorders; Burning mouth syndrome;
Neuropathic pain syndromes
Introduction
Chronic orofacial pain (COFP) disorders, collectively, affect a large
proportion of the population [1]. They can involve dysfunction in
multiple systems: musculoskeletal, vascular, neurovascular,
neuropathic, idiopathic, and psychogenic [2]. Further, they can present
singly or in combination. Even when a COFP disorder is associated
with a single cause (e.g., neuropathic), it can present with a range of
clinical features. Hence, it is common for COFP patients to consult
multiple providers before an accurate diagnosis is made, including
primary care providers, dentists, physical therapists, and mental health
professionals. While several COFP diagnoses are relatively common
(e.g., migraine, tension-type headache, and temporomandibular






















*These conditions are not included in this manuscript as they are not considered
COFP
Table 1: Classification of neurologic, idiopathic, and musculoskeletal
orofacial pain [3].
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This delays the initiation of effective treatment for years in patients
with some of the less common conditions [4]. COFP syndromes may
arise from a variety of underlying pathophysiologic causes and are
typically categorized as musculoskeletal, vascular, neurovascular,
psychogenic, neuropathic (episodic or continuous), and idiopathic [3].
Burning Mouth Syndrome (BMS) is one of the less common
neuropathic/idiopathic COFP disorders. While most neuropathic
and/or idiopathic COFP conditions are relatively uncommon,
collectively, they are reasonably prevalent in the general population,
affecting between 3.3% and 8.2% of that group [5]. To a large degree,
the broad range reflected in such epidemiologic studies reflects the lack
of specific clinical signs and symptoms that can be used to reach a
definitive diagnosis for neuropathic/idiopathic COFP. Not only does
the lack of definitive diagnostic criteria complicate epidemiologic
studies, diagnosis and treatment are complicated by the fact that many
of these COFP disorders, as diagnoses of exclusion, often suffer from
misdiagnosis or delayed diagnosis (Table 2).
Site Pain severity pattern Pain descriptors Aggravating factors Possible H and Pfindings
Burning Mouth Syndrome
Labial mucosa (frequently





Mild to moderate severity.
Burning, stinging, scalding,
and numb. Usually bilateral.
Hot or spicy food. Stress?








Along distribution of 2nd and
3rd divisions of trigeminal
nerve
Paroxysmal. Attacks last
seconds to minutes. Many (up to
30) attack daily.




Chewing, light touch, talking, brushing
teeth, cold. Sometimes spontaneous.








Moderate to high severity.
Stabbing, sharp.
Swallowing, chewing, talking, coughing,

















Tooth pain or pain at the site
of a tooth extraction. More
often in molars and in
maxilla.
Continuous or almost
continuous. Usually localized to
tooth at onset. Can spread to
















ear. May include pain
radiating to head and neck.
Usually intermittent. Can
progress to continuous with
exacerbations.
Mild to high severity.
Aching, sharp. Prolonged chewing. Bruxing.







Table 2: Burning mouth and other neuropathic/idiopathic COFP disorders: Differential diagnosis.
This manuscript focuses primary attention on one idiopathic/
neuropathic disorder, Burning Mouth Syndrome (BMS). It reviews the
clinical features of BMS, putative mechanisms underlying its
presentation, psychological factors often associated (BMS often has
been misdiagnosed as “psychogenic”), and a review of empirical data
relevant to treatment. In addition, the manuscript reviews the clinical
characteristics of other neuropathic COFP disorders. Because most
cases of COFP, including BMS, lack the level of medical evidence
required for a definitive diagnosis, a practitioner needs to know both
the characteristics of a given condition (i.e., the hallmarks of BMS) and
those of other neuropathic/idiopathic conditions in sufficient detail so
as to develop an appropriate differential. Before focusing specifically
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on BMS and other associated disorders, however, we first review a
grading system that has proved to be useful in making clinical
diagnoses across a broad range of neuropathic disorders.
Diagnosing Neuropathic Pain Disorders
Neuropathic pain is defined as “pain initiated or caused by a
primary lesion or dysfunction in the nervous system” [6]. Historically,
neuropathic pain has been under-recognized in primary care settings
[7]. In an effort to facilitate diagnosis and the initiation of appropriate
treatment, the Special Interest Group on Neuropathic Pain (NeuSIG),
under the auspices of the International Association for the Study of
Pain, developed a grading system to facilitate its diagnosis [5,8].
Figure 1 describes a decision tree for determining whether the
medical evidence associated with a patient’s symptoms support the
diagnosis of a neuropathic disorder as "definite," "probable," or
"possible."
In order to reach a definite diagnosis, a practitioner must find
confirmatory evidence on diagnostic testing or make a disease
diagnosis consistent with the neurologic dysfunction. As is evident in
the following pages, such evidence often is lacking in neuropathic
COFP disorders.
Thus, the differential diagnosis of these conditions typically rests on
a thorough history, a careful physical examination, and an
understanding of the clinical features with which the disorders may
present (Figure 1) [9].
Figure 1: Diagnostic guidelines for neuropathic pain [8].
Burning Mouth Syndrome
Clinical features
Burning Mouth Syndrome (BMS), or glossodynia, is a chronic pain
disorder characterized by continuous, burning sensations that fluctuate
in intensity and often are associated with taste alterations (dysgeusia)
and dry mouth (xerostomia) [10]. These symptoms most often affect
the anterior two-thirds of the tongue and other oropharyngeal
structures. Estimates as to its prevalence vary widely with some studies
reporting prevalence as low as 0.7% of the adult population, while
others have estimated prevalence to be as high as 15% [11,12]. The
wide variability evident in these studies likely reflects two elements
that complicate its diagnosis:
1) There is no clear understanding of the neurophysiologic
mechanisms underlying the symptoms, so that BMS lacks a
confirmatory diagnostic test; and
2) BMS symptoms can be secondary to other medical (e.g.,
nutritional deficit) or oral/dental conditions (e.g., an ill-fitting bite
splint or an inflammatory reaction to an oral appliance) that must be
ruled out as causes. In the latter cases, BMS pain is considered
“secondary,” while BMS pain that is not secondary to other medical or
oral/dental conditions is considered “primary.” Many surveys do not
distinguish between primary and secondary BMS.
Prevalence
While there is a lack of agreement as to its prevalence, other features
are more consistent. For example, BMS is most commonly found in
older adults (average age of onset is ~ 60 years) and is rare in patients
younger than 40 [13]. Further, it is as much as five times more frequent
in women than men. Because it is so frequently found in peri- or post-
menopausal women, there is a growing conviction that its onset may
be related to hormonal factors [14,15]. Similarly, there is growing belief
that the pain and other symptoms of BMS are neuropathic in nature,
largely owing to the typical descriptions [14,16]. While BMS typically
presents as pain distributed symmetrically in the oropharyngeal area,
that pattern can vary. It also tends to follow a typical diurnal pattern,
such that patients often complain of pain that increases throughout the
day. Most patients also report that pain is exacerbated by hot or spicy
foods and is eased by cold foods.
Pathogenesis
The exact pathogenesis of BMS is in large part poorly understood.
Psychogenic contributors likely play a role in the presentation of
symptoms, as does hormonal fluctuations. No studies offer conclusive
evidence of an identifiable etiology, however, symptoms of BMS have
been reported in higher incidence in persons with significantly
heightened perception of taste, increased number of fungiform
papillae, and potentially the presence of the TAS2R38 gene [14]. Given
the bilateral nature of the symptoms, it can be reasonably hypothesized
that BMS represents a type of central pain.
Psychological factors
While psychological disorders are no longer seen by most as causing
BMS, they frequently are associated with the disorder [13,17].
Research has found a high incidence of depression, anxiety, and fear of
cancer in patients with BMS. In fact, between 30% and 50% of BMS
patients have been found to experience symptoms of depression and
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30% to 60% have been found to report symptoms consistent with an
anxiety disorder [18,19]. Certainly, these conditions can co-exist.
While the frequency of these comorbidities seems high, it is
important to note that the data reflect the presence of depressive or
anxiety symptoms that may not meet the criteria for a formal
psychiatric diagnosis, such as a Major Depressive Disorder. In this
respect, BMS is similar to other chronic pain conditions where high
rates of sub-syndromal psychological disorders also have been found.
For example, epidemiologic studies based on health claims databases
show diagnoses of depression in 13% of patients with chronic low back
pain, while symptom-based (i.e., sub-syndromal) studies of clinic
patients report depressive symptoms in almost 75% of patients with
chronic pain [20,21]. Inasmuch as the symptom profile described
above is consistent for BMS patients and patients experiencing other
chronic pain conditions (e.g., low back pain, fibromyalgia), these co-
morbidities cannot be considered unique to BMS [21,22]
More unique to BMS compared to other orofacial pain syndromes is
the frequency with which patients fear that their symptoms reflect an
underlying malignancy. Multiple studies have reported that a high
percentage of BMS patients describe a fear of cancer, ranging from 20%
to 47% [23,24]. While any explanation of this unusual finding is
speculative, it likely reflects several factors. First, as BMS is a diagnosis
of exclusion, the lag between symptom onset and diagnosis can be
protracted. Research has shown that on average, patients with BMS
may await a diagnosis for almost 7 years [3]. Hence, patients often
experience an extended period of uncertainty regarding potential
causes of their symptoms, during which time anxiety and catastrophic
cognitions may develop. A second factor that likely contributes to
cancer phobia involves BMS demographics: patients average 60 years
of age at the time of BMS symptom onset. Cancer, as a disease
associated with aging, is a much more prominent concern for the latter
age group than for other chronic pain conditions, where onset
commonly occurs at a younger age.
Treatment considerations
While treatment for BMS patients lacks evidence-based or
consensus guidelines, the first step invariably involves ruling out other
conditions that might be responsible for the symptom profile. Ill-fitting
bite splints and selected acrylic appliances can result in inflammation
and discomfort, while correcting the design and/or composition of the
appliance can yield symptom relief [10]. In addition, metabolic
disorders (e.g., diabetes) and nutritional deficiencies (e.g., Vitamin B12
deficiency) may represent other conditions that can occasion BMS
symptoms [14]. Finally, BMS symptoms can be associated with adverse
effects of medications. For example, select anti-depressant medications
are frequently associated with side effects such as dry mouth, a
frequent part of the BMS profile. In these cases, the replacement of a
problematic medication with another that has a different side effect
profile can be helpful in reducing secondary BMS symptoms.
For patients with primary BMS, the practitioner may want to adopt
a “stepped care” model [25]. In this model, treatments are staged so
that front-line, often less expensive treatments are initiated first with
many patients responding to initial therapy. Of course, front-line
treatments for primary BMS typically are dental or medical in nature.
The following section outlines medical therapies with demonstrated
effectiveness for BMS.
Pharmacological therapies: Several pharmacological agents have
been studied as possible treatments for BMS although typically the
evidence is from small, poorly designed studies, many of which lack
blinding, randomization, and/or comparison to a placebo (an
important consideration inasmuch as a demonstrated placebo effect
exists in treating this pain syndrome). When combined with the
subjectivity of pain assessment over a relatively short duration of
treatment, these design considerations weaken some of the findings.
Overall, this translates into low quality evidence to support efficacy
and safety [26]. For this reason, non-pharmacological approaches to
the management of this condition should be considered before
initiating drug therapy.
As there is no standardized, clinically validated pain assessment tool
specific to BMS, no consensus exists on how to effectively rate BMS
pain. Therefore, some inconsistencies in results among trials may be
secondary to how pain scores are characterized and interpreted. In
addition, most studies did not assess the impact of treatment on quality
of life (QOL). Notwithstanding these concerns, given the burden of
pain and impact on QOL in those suffering from BMS,
pharmacotherapeutic options may be reasonable once other etiologies
are considered and other non-pharmacologic treatment options have
failed. Unfortunately, many drug therapy studies have failed to show a
substantial clinical benefit versus placebo for the treatment of BMS
pain. When drug therapy is appropriate, co-occurring conditions are
an important consideration in tailoring treatment to other patient-
specific factors and needs.
Clonazepam: It has been proposed that GABA-A receptors may
change in density or ligand concentration, resulting in the pain
associated with BMS. As clonazepam modulates GABA-A receptors
and has a strong effect on the brain’s serotonergic system, it has been
widely studied as a treatment for BMS, both systemically and topically.
It is thought that clonazepam is the preferred benzodiazepine for
treating BMS, partially due to its unique pharmacokinetic profile [27].
Observational and interventional studies of clonazepam have
evaluated topical administration of the drug (e.g., 0.5 mg clonazepam
dissolved in the mouth for three minutes then spit out with remaining
saliva up to four times daily), as well as once daily, low-dose systemic
use [27-36]. With topical administration, clonazepam's action has a
quick effect in reducing BMS symptoms (within 10 minutes) and is
association with minimal adverse effects. Unfortunately, the duration
of action of analgesia and alleviation of other BMS symptoms is short
(3 hours to 5 hours) [15].
One randomized, placebo-controlled study that assessed topical
clonazepam found superior pain relief as compared to placebo over six
months of treatment [32]. At one month, 23/33 showed a 50%
reduction in symptoms vs. 4/33 in the placebo group (p<0.05). Similar
findings were reported at six months: 23/33 on clonazepam
experienced a 50% reduction in symptoms from baseline vs. 2/33
taking placebo. Although further studies would be beneficial to
confirm these findings, topical clonazepam is a viable treatment in
patients unresponsive to other treatments not associated with abuse-
liability.
The efficacy of systemic clonazepam is generally conflicting among
widely variable studies. Some studies didn’t demonstrate added clinical
value over placebo, while other studies showed significant
improvement in symptoms related to pain intensity and overall
improvement.
Antidepressants: Efficacy regarding the use of antidepressants for
the treatment of BMS is also conflicting, with drug-related side effects
of greater concern. Trazodone, an antidepressant with multiple actions
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involving the serotonergic system, has been studied for pain due to
BMS. One randomized, double-blind, placebo-controlled study
assessing the use of trazodone over 8 weeks showed no benefit vs
placebo in pain intensity [37]. Moreover, use of trazodone was
associated with adverse effects that included dizziness and drowsiness.
Though small studies assessing the use of sertraline, paroxetine, and
moclobemide have demonstrated favorable efficacy results, confidence
in those results is limited by the lack of placebo comparisons and
blinding [38,39]. Aside from the methodological considerations
associated with the latter studies, dose-dependent adverse effects and
drug interactions limit these drugs’ usefulness. However, general
provider comfort in dosing and monitoring of these agents may make
them reasonable options for the patient experiencing pain due to BMS.
Milnacipran is a serotonin and norepinephrine reuptake inhibitor
that is approved in the U.S. to treat fibromyalgia, rather than
depression, even though it shares common pathways with the latter
antidepressant drugs [40]. Three open-label, non-controlled studies
have assessed the use of milnacipran for treatment of BMS [41-43]. As
with the antidepressant literature, results were conflicting, and their
interpretation complicated by such methodological issues as small
sample sizes, possible bias, and a lack of comparators. Other confounds
included the use of other drugs and the presence of other co-occurring
conditions, all of which raise further questions about the quality of the
evidence. Hence, the data provide little support for its use.
Vitamin B: Vitamin B has been studied for the treatment of BMS,
but has also been used to treat other causes of burning mouth
symptoms, such as vitamin deficiency. Different types of Vitamin B
have been studied, including B1, B2, and B6. In one open-label, non-
randomized study of 55 patients with BMS (with and without vitamin
deficiency), 86% (24/28) of vitamin-deficient participants were
asymptomatic at three months; however, only 7% (2/27) of non-
deficient participants exhibited improvement [44]. In addition, A
double-blind, non-randomized study of 16 patients found no benefit of
Vitamin B (Vitamin B1, B2, and B6) VS placebo after four months of
treatment [45]. Unfortunately, the study did not control for vitamin
deficiency status. Based on available evidence, treatment with Vitamin
B should be considered only if the patients are established to be
vitamin deficient.
Gabapentin: One double-blind study assessed the use of gabapentin
and ALA, alone and in combination, for the treatment of BMS pain. A
total of 120 participants were randomized to one of four groups:
gabapentin 300 mg daily, ALA 600 mg daily, the combination of both,
or placebo [46]. Greatest efficacy (noted as positive changes or full
recovery) was found with combination therapy (14/20 patients)
relative to ALA (11/20 patients), gabapentin (10/20 patients), and
placebo (9/60 patients). Adverse events were mild with no reported
discontinuations. While these results provide some support for the
combined treatment, the added benefits of the combined treatment
were modest. Further, dose dependent adverse effects (e.g.,
somnolence, dizziness) might limit the use of gabapentin. Sub-
therapeutic dosing of gabapentin compared to studies assessing its
utility in other chronic pain syndromes may have contributed to the
modest effect size.
Capsaicin: Topical capsaicin works by desensitizing nociceptors and
depleting stores of the neuropeptide, Substance P, thereby reducing
neuropathic inflammation and potentially leading to a reduction in the
oral burning sensation characteristic of BMS. A study utilizing oral
capsaicin was shown to have statistically significant improvement in
visual analog score (VAS) ratings, but with the complication of serious
gastric pain in 32% of the participants by the end of 4 weeks [47]. This
is not surprising considering the typical adverse effect of burning when
initiating this therapy for topical use. While other capsaicin studies
also have shown reductions in VAS scores for BMS patients,
formulations varied among studies, making interpretation difficult
[48,49]. Hence, capsaicin may be an effective agent in reducing
symptoms of BMS but its use is limited by poor patient tolerability and
a lack of information regarding the optimal dose.
H2-Receptor antagonist (Lafutidine): Lafutidine is an H2-receptor
antagonist that has a unique mechanism related to the treatment of
BMS as compared to other drugs within the class. Lafutidine is thought
to activate mucosal defensive mechanisms in the gastrointestinal tract
by sensitizing capsaicin-sensitive afferent neurons. One randomized,
controlled study has demonstrated benefit for lafutidine 10 mg twice
daily in treating 74 patients with BMS [50]. The control group received
other H2RAs twice daily, and both arms rinsed with an anti-
inflammatory solution (azulene) four times daily. After 12 weeks of
treatment, those treated with lafutidine reported lower pain intensity
relative to comparators. Although the difference was not statistically
significant, complete symptom resolution was observed in 29% of
those treated with lafutidine vs. 13% in the control arm. Minor adverse
effects not warranting discontinuation were noted with lafutidine,
including mild nausea and abdominal distention. Unfortunately,
lafutidine is not available in the United States and the observable
differences seen in treatment groups may preclude assuming the utility
of this agent is a class-effect of HSRAs in general.
Complementary alternative medicine: Various complementary
alternative medicines (CAM) have been studied for treatment of BMS.
Several compounds have been shown not to differ in efficacy from
placebo. Generally, the alternative medicine studies lack strong
evidence of clinical efficacy (e.g., comparisons to placebo or other
controls) and/or are limited by unknown safety concerns. For these
reasons, utilization of these as bona fide treatment options for BMS is
not recommended. That said, a reasonable amount of CAM research
on BMS has been conducted.
Alpha Lipoic acid: Although the mechanism of BMS is not well
understood, as noted above, some believe a neuropathic component
may be involved. Alpha lipoic acid (ALA) has been used to help treat
diabetic neuropathies and is believed to have a neuroprotective effect
as an antioxidant and free radical scavenger. It also increases levels of
glutathione and lowers blood glucose levels although the clinical
significance of these pharmacologic actions are unknown [51].
Accordingly, ALA has been studied as a treatment for BMS.
Evidence regarding the efficacy of ALA for treatment of BMS is
conflicting, complicated in part by differing definitions of efficacy
among studies. Several randomized, blinded, controlled trials have
demonstrated positive efficacy of ALA at improving pain [46,51].
Further, several studies have shown adverse effects to be mild and
primarily involving gastrointestinal complaints [46,52]. Other studies,
however, have shown no benefit of ALA as compared to placebo
[52-54]. Although more studies are needed to clarify the efficacy of
ALA in the treatment of BMS, overall evidence suggests that ALA may
be somewhat effective for treatment of BMS. Moreover, ALA is
relatively safe, with few side effects or drug/disease interactions. ALA is
inexpensive and available without a prescription, although lack of
consistency in commercially available products may complicate
accurate dosing.
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Lycopene: Lycopene was examined for treatment of BMS in a
double-blind, placebo controlled study [55]. Sixty BMS patients were
randomized to either lycopene-enriched olive oil 300 ppm or placebo
(water and dye) for 12 weeks. Lycopene was administered orally as 1.5
ml of spray three times daily. Results showed improvement in both
groups in VAS pain scores and other BMS symptoms, and no adverse
events were reported. No statistically significant differences, however,
were found between groups. Similarly, a randomized, double-blind
study of Hypericum perforatum extract 300 mg (n=21) vs. placebo
(n=22) three times daily resulted in no statistical differences in VAS
scores between groups at 12 weeks [56].
Catuama is an herbal product composed of four medicinal plant
extracts: Paullinia cupana (guarana), Trichilia catigua (catuaba),
Zingiber officinalis (ginger) and Ptychopetalum olacoides
(muirapuama). Catuama twice daily was compared to placebo in a
randomized, double-blind study in 72 patients with BMS [57].
Statistically significant reductions in pain severity ratings favoring the
catuama-treated group were noted at 8 weeks and 12 weeks. Six
participants (3 in each arm) withdrew due to exacerbation of
symptoms. Adverse effects also were noted for catuama, including
somnolence, weight gain and insomnia. While the long-term safety of
this product is unknown, abrupt discontinuation of one of its
components, guarana, can result in symptoms of withdrawal because
of its caffeine content [58].
Other agents: Other agents, such as olanzapine, topiramate and
pramipexole, have only been reported descriptively in the literature
[59-62]. In one case report, topiramate was proposed to induce BMS.
Other therapies such as sucralose and hormone replacement have been
studied for secondary causes of burning mouth pain versus BMS itself
[59].
Psychological therapies: Patients not responsive to dental or
pharmacologic treatments may require multi-disciplinary care that
includes psychotherapy. In addition, patients demonstrating symptom
reduction but not total or adequate resolution may benefit from
psychological intervention to supplement medical/dental treatment.
Although cognitive behavioral therapies have been recommended as
part of a multidisciplinary intervention for BMS patients, the empirical
literature regarding the effectiveness of psychological interventions is
limited to studies of group therapies [63,64]. For example, in an early
study, BMS patients were randomized into a cognitive therapy group
that met weekly for 12 weeks to 15 weeks or into an attention control
group [65]. The treatment group demonstrated a statistically
significant decrease in reported pain severity following treatment. That
benefit was maintained at six-month follow-up. Similar results were
obtained in a more recent study of a three-month course of group
psychotherapy against treatment as usual [66]. A significantly higher
percentage of the group therapy participants reported symptomatic
improvement than did patients who participated in standard care (70%
Vs. 40%). Finally, one study examined the effects of group therapy (two
psychoanalytic sessions per week for two months) crossed with
medical treatment (ALA) or placebo. Results at two months showed
that all active treatments yielded symptom improvement relative to
placebo, although the greatest improvement occurred in the ALA and
group therapy condition [67].
While the above findings suggest benefit from group interventions,
the mechanisms responsible for symptom improvement are not clear,
especially as each of the above interventions differed in the content of
the intervention from the others. Indeed, the issue is highlighted
further by results derived from a very brief group intervention [68].
The latter intervention, described as group cognitive behavioral
therapy, involved two 20-minute presentations (by a neurologist and a
dentist) to small groups of BMS patients. The presentations provided
basic information regarding BMS, pain physiology and stress, as well
as brief training in relaxation; this was followed by an hour of open
discussion among group participants. The session then was repeated at
an interval of six months. Despite the brevity of the intervention,
significant reductions in pain intensity and anxiety are described
relative to symptoms reported by patients who received treatment as
usual.
The results described above suggest that psychological
interventions, even some that are quite basic, can be useful adjuncts to
the treatment of BMS. These results also raise questions about how
intensive such interventions should be, especially as benefits have been
found for both brief and more extended interventions. As with the
medical treatment modalities, the best approach could involve
“stepped care”-a set of interventions that are scaffolded, such that less
intensive/costly interventions are delivered initially (e.g., interventions
with an educational focus) and are followed by more intensive
interventions only for patients that do not benefit from the previous
level of care [69]. With such a model, psychological distress that
accrues over the extended course of the search for diagnosis and
treatment would likely be responsive to a low-level intervention, while
patients who bring pre-morbid psychosocial vulnerabilities to the
clinic would likely require more intensive care [3].
Other Neuropathic/Idiopathic COFP Disorders
Trigeminal Neuralgia
Trigeminal neuralgia (TN) is an orofacial pain condition that is
characterized by paroxysms of sharp, stabbing, and electric, shock-like
pain that typically follows either the 2nd branch or the 3rd branch of
the trigeminal nerve unilaterally to the cheek or chin. Usually episodes
last several seconds, but can last for several minutes in duration.
Patients often describe periods in which painful episodes are frequent
for several weeks followed by pain-free intervals lasting months or
years. The pain generally is of high severity and frequently triggered by
stimulation of “trigger zones” that is typically of a light mechanical
nature (e.g., brushing, talking, and shaving). Provocation can also be
associated with other stimuli, such as bright lights or loud sounds.
Two categories of TN have been identified. Symptomatic TN is
characterized by an identifiable structural lesion, such as nerve
demyelination. Classic TN, while technically considered to be
idiopathic, is thought to be related to vascular compression of the
trigeminal nerve root at the root entry zone. This can result in focal
demyelination and hyperexcitability of the afferent fiber.
Hyperexcitability of the trigeminal brainstem complex also is
suspected in TN, perhaps, as a consequence of repetitive “ignition” of
the injured sensory nerve (i.e., central sensitization). If so, this could
account for the effectiveness of pharmacotherapies that target the
central nervous system (CNS).
TN is a relatively uncommon condition, with estimates of incidence
that vary from a low of 4.3 new cases per 100,000 annually to rates as
high as 27 per 100,000 [70,71]. Rates also vary significantly with age,
with very few young adults experiencing TN and a much higher
incidence in adults over 60 years of age, reaching rates as high as 80 per
100,000 annually among adults over 70 [71,72]. It is more frequently
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found in women than men, with recent studies estimating the relative
rates at 2.3 to 1 [73].
Differential diagnosis of TN is generally clinical in nature although
ruling out metabolic and endocrinologic etiologies is important.
Imaging may be pursued in an effort to further classify the syndrome
and rule out structural causes that may be alleviated by surgical
correction. Although TN is almost always unilateral in nature,
following the respective dermatome(s) of the nerve branches affected,
bilateral distribution of symptoms has been described. Differentiating
between TN and other facial neuralgias may be difficult, at best.
Suspicion of active herpes zoster infection in and around the
ophthalmologic orbit (herpes zoster ophthalmicus) should be
specifically ruled out as a possible cause of symptoms and high
suspicion of this disorder resulting in referral to a specialist [74].
Psychological factors in TN generally are viewed as “downstream”
phenomena associated with the prolonged experience of severe,
lancinating pain. Consistent with that view, research has shown that,
relative to patients with lower pain severity, those with more severe TN
pain describe more disability and more impaired health status [75].
Further, in a study that compared patients with chronic, atypical facial
pain against those with both atypical facial pain and episodic TN,
those with both atypical pain and TN reported significantly higher
levels of pain severity, pain-related disability, anxiety, and depression
[76].
Many non-pharmacologic, pharmacologic, complementary, and
surgical interventions have been extensively studied for the treatment
of pain due to TN and are beyond the scope of this manuscript [77]. In
general, antidepressants and anticonvulsants are the mainstay of
pharmacologic therapy with perhaps carbamazepine, gabapentin,
pregabalin, tricyclic antidepressants, and duloxetine being the most
widely studied [78]. Given the neurogenic nature of TN, it is not
surprising that therapies that have shown efficacy for other
neuropathic pain syndromes also show promise for TN. As with most
chronic pain syndromes, multi-disciplinary treatment involving
cognitive behavioral therapy also has shown promise.
Glossopharyngeal neuralgia
Glossopharyngeal neuralgia (GPN) symptoms are similar to those
of TN: attacks of pain of a sharp, stabbing, shooting, or lancinating
nature that typically is unilateral (although 25% of patients may have
bilateral symptoms) and that typically lasts less than a minute. In
addition to pain, some patients also experience some throat discomfort
owing to the innervation of glossopharyngeal (cranial IX) nerve [71].
Following an attack, it is common for patients to experience a series of
episodes of GPN-related discomfort at a frequency of 5 hour to 12 per
hour; clusters of such attacks can occur for weeks or months [71,79].
Subsequent to a GPN cluster, however, many patients experience a long
symptom-free period with up to 75% experiencing complete remission
[80]. This type of symptom clustering makes systematic investigation
of treatment modalities incredibly difficult.
There are two forms of GPN, secondary to the differences in the
pain distribution associated with each form. Pharyngeal GPN usually
is located in the pharynx, tonsil, soft palate, or posterior one-third of
the tongue, with radiation to the ear and/or mandible possible.
Tympanic GPN pain, however, is generally restricted solely to the ear
for unclear reasons. Regardless of the form, GPN triggers generally are
located in the tonsillar region and posterior pharynx, so that attacks
can be activated by swallowing, chewing, talking, coughing, or
yawning [79]. In the majority of cases, a thorough examination of the
patient is unrevealing of pathology, other than the identification of
trigger points [81].
GPN is an uncommon condition, with an incidence estimated
around 0.7 cases/100,000 per year, substantially lower than that of TN.
It occurs predominantly in adults, typically over the age of 50, and is
twice as common in women as men [71]. Secondary to its rarity, it is
difficult to diagnose, with the differential diagnosis most frequently
between TN and GPN, although the referred mandibular pain also can
be confused with temporomandibular disorders, a much more
common group of pain syndromes [82].
No studies were found that address psychological assessment of
patients with GPN, nor were studies found that addressed GPN-
specific treatment. That said, given the similarities described above
between TN and GPN, many of the same recommendations are likely
to apply. In particular, it is likely that GPN patients who experience
severe symptoms, especially those who experience GPN symptoms on
a recurrent basis, are likely to demonstrate QOL effects similar to those
of TN patients [75]. Those patients may benefit from complementary
psychiatric (i.e., anti-depressant) or psychological treatment [83].
Similar to BMS, GPN lacks clear evidence-based or consensus
diagnostic or treatment guidelines. Additionally, the lack of
predictability in presence of symptoms makes designing well-
controlled studies difficult. Several treatment modalities have been
investigated and treatment options for GPN typically follow that of a
plan for TN. As with the other COFP syndromes discussed already, a
multi-disciplinary approach to treatment, including psychologic
modalities, should be made available to patients.
Post-herpetic neuralgia
Acute herpes zoster eruptions are associated with reactivation of
latent varicella virus infections, often occurring decades after the initial
infection. Acute zoster infections are common in the general
population, with the lifetime risk as high as 20% and increasing with
age [84]. The eruptions typically follow a dermatomal pattern and
occur in the thoracic region in up to 50% of patients, in the trigeminal
region in 5% to 28% of cases, and in cervical nerves in approximately
20% of those diagnosed [85-88]. Approximately 10% of patients with
acute herpes zoster will experience postherpetic neuralgia (PHN),
defined as pain of at least moderate severity (>3/10 on a 0 to 10 scale)
that persists for more than three (3) months after the herpes zoster
rash has healed [84,89]. When PHN is defined differently (e.g., at a
lower severity) and an older age group is the study target, the incidence
of PHN can be as high as 73% [90].
Factors that predict the pain severity in acute herpes zoster have
been well studied with several factors appearing as consistent
predictors: older age, acute pain severity, and the presence of a
prodrome [91]. In turn, several factors have been found to predict
PHN pain severity: older age, acute pain severity, and previous or most
recent rash severity [85,92,93]. In addition, functional limitations prior
to an initial infection have also been found to predict PHN pain
severity [85]. PHN pain has been described variously as deep, aching,
burning, stabbing, itching, and electrical. It can be the product of
several different mechanisms:
1) allodynia (an ordinarily non-painful stimulus is perceived as
painful);
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2) hyperalgesia (a somewhat painful stimulus is perceived as more
painful than expected); and
3) dysesthesia (abnormal sensations are experienced in the absence
of stimulation). Of these, the pain of allodynia is often described as
most debilitating by PHN patients [94,95].
The pathophysiology of PHN is complex, involving a combination
of peripheral and central mechanisms. Peripheral factors involve injury
to nerves secondary to inflammation and the immune response to the
varicella infection; the damage can involve both nociceptive (i.e., C-
polymodal and αδ) and non-nociceptive fibers (i.e., αβ) [96]. In
addition to the peripheral inputs, central sensitization also is believed
to contribute to PHN pain, secondary to the deafferentation associated
with peripheral nerve damage.
The differential diagnosis of PHN is based on a sound physical
examination, and perhaps more importantly, a thorough history of
symptoms and past medical problems. Pain and dysesthesia may
precede the appearance of rash in an acute zoster infection, which may
make differentiation from PHN and the appropriate treatment
approach less clear.
A substantial literature documents an association between the
severity of PHN pain and a patient’s QOL: higher levels of pain severity
are associated with depression and anxiety in high percentages of PHN
patients [97-100]. Moreover, PHN pain is likely to cause such
emotional responses: patients with acute herpes zoster whose pain
resolves (typically after approximately one month) do not demonstrate
the levels of emotional distress exhibited by patients whose PHN pain
persists [94]. PHN pain, however, can impact other QOL domains, as
well, including disability/role functioning and sleep [97,99,100]. There
also is some evidence that patients who cope poorly with the pain of
acute infection may be at greater risk of developing PHN: patients who
catastrophized at higher levels at baseline were likely to report higher
levels of pain severity when assessed 8 weeks later and may have been
more vulnerable to developing depression over the course of the study
[101].
Much research has focused on the early implementation of
pharmacologic modalities during an acute zoster outbreak (e.g.,
corticosteroids, anti-virals, and anticonvulsants) to reduce the later
appearance of PHN symptoms [102,103]. Numerous non-
pharmacologic and pharmacologic treatments have been studied for
the treatment of pain associated with PHN. These treatment options
generally follow similar strategies to that of other common
neuropathic pain disorders [104]. Of those investigated various
antidepressants, namely tricyclic antidepressants (e.g., amitriptyline or
nortriptyline) and anticonvulsants. Topical lidocaine is FDA approved
for PHN, although studies supporting its use are small with modest
treatment effect [105,106].
Atypical Odontalgia
Atypical odontalgia (AO) involves “a severe throbbing in the tooth
without major pathology” [15,107]. Because AO is idiopathic, its
diagnosis can be challenging and typically is a diagnosis of exclusion. It
is common, however, for AO to begin following a dental procedure,
such as a tooth extraction or pulp extirpation [81] It is most often
found in women in their mid-forties, although it can affect adults of
any age [107] While the mechanisms of AO remain unclear, it is
increasingly thought that it is occasioned by several events or risk
factors that include local inflammation, infection, mechanical
irritation, and minor nerve injury.
No evidence-based diagnostic guidelines exist for AO which makes
the systematic evaluation of treatment modalities difficult.
Unfortunately, therapies typically effective for other orofacial pain
syndromes have been largely disappointing in studies of AO [108].
Eagle’s syndrome
Eagle’s syndrome is characterized by a constellation of features that
may include recurrent throat pain, foreign body sensations in the
pharynx, dysphagia, ear pain, and neck pain [109]. These symptoms
can be exacerbated by head rotation, swallowing, chewing, and
speaking. Rarely, Eagle’s syndrome can be associated with “yawning
headache” [110]. The symptoms are related to elongation of the styloid
process, normally 2.5 cm to 3 cm in length, to a length exceeding 3 cm.
At this length, a range of neurovascular structures near the tip of the
styloid process can be stimulated. Interestingly, elongated styloid
processes are not uncommon: it is estimated that 4% of the population
will exhibit elongation, although it is symptomatic in only a small
percentage of that group [111]. In the latter group, it is thought that
ossification and/or scar tissue formation may be responsible for
symptom onset, sometimes following tonsillectomy [112].
Two forms of the syndrome have been identified: classic type and
carotid artery type. The classic type is associated with stimulation of
the trigeminal, facial, glossopharyngeal, and vagus nerves, while the
carotid artery type is linked to styloid irritation of the carotid nerve
plexus [113]. Symptoms associated with Eagle’s syndrome can be
similar to those of GPN, although those of the former syndrome tend
to be more dull and persistent, while those of the latter can be more
sharp and episodic. Eagle’s syndrome symptoms also have been
misdiagnosed as TN and as a temporomandibular disorder [109,112].
For patients with moderate symptoms, medical management is
advocated, although no clear preference has emerged for optimal
pharmacologic benefit. A range of medications has been tried that
include non-steroidal anti-inflammatory medications, anti-
convulsants, and anti-depressants, all of which have yielded
satisfactory results [114]. Similarly, transpharyngeal infiltration with
steroids or analgesics has proved effective. Physical therapy approaches
also have been tried, including manual therapy and exercise, although
with mixed results [115].
For patients with severe symptoms, surgical interventions have
proved effective. Two approaches are used, an extra- and an intra-oral
[112]. There is some disagreement as to which is preferred as both have
demonstrated good success [109,112]. While the intra-oral approach is
somewhat less invasive, complications such as poor visualization of the
surgical field, injury of local structures, and infection have caused the
current preference toward extra-oral approaches secondary to better
visualization and a reduced risk of infection [116].
Headache Disorders
As noted previously, headache disorders, whether of
musculoskeletal (e.g., tension-type) or neurovascular (e.g., migraine)
origin, differ in their clinical presentations from the disorders of
primary interest in this manuscript and, consequently, are not a major
focus. That said, headache disorders are common and are considered
by some to be another form of COFP [2]. Further, in some cases,
headache disorders can mimic neuropathic/idiopathic COFP
symptoms (e.g., some temporomandibular disorders [TMD]) and,
more commonly, can complicate treatment as co-existing conditions.
For these reasons, headache disorders warrant mention here. More
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attention is paid to TMD than to other headache conditions (migraine,
cluster, tension type) as its symptoms can mimic neuropathic/
idiopathic disorders in some patients.
Temporomandibular disorders
Unlike BMS, TMD is a positive diagnosis (i.e., it can be diagnosed
when an identifiable set of physical observations and symptoms are
found), rather than a diagnosis of exclusion. Characteristic TMD
symptoms include pain on palpation of the masticatory musculature,
pain on jaw opening, restricted jaw opening, and clicking or crepitus
on jaw opening. Patients commonly report pain that is more
widespread than just the masticatory musculature and are likely to
report headaches and pain elsewhere, even low back pain [117].
Patients with TMD also demonstrate a number of parafunctional oral
behaviors that can support clinical examination findings [118]. In fact,
patients that exhibit high levels of parafunctional activity are 17 times
more likely to have a TMD disorder than patients with low levels of
such activity [117]. Finally, the medical history reported by TMD
patients also can support a diagnosis: they are more likely than non-
TMD patients to describe an external injury to the jaw, a jaw injury
due to yawning, or a jaw injury associated with prolonged opening.
Also unlike BMS, TMD is quite prevalent. The 2002 National Health
Interview Survey suggests that approximately 4.6% of U.S. adults (6.3%
for women; 1.8% for men) reported symptoms consistent with TMD
[119]. Moreover, it has been estimated that as much as 75% of the
population has at least one of three TMD signs: joint noise, deviation
on opening, or episodic locking [120]. As a consequence of its
prevalence, TMD has been the target of a large project, the Orofacial
Pain: Prospective Evaluation and Risk Assessment (OPPERA) study
[121]. Because this project followed a large sample of asymptomatic
individuals to the point where a substantial number experienced a first
instance of TMD, prospective OPPERA studies have examined medical
and psychological factors associated with the onset of the condition,
providing predictive data not available for the idiopathic/neuropathic
disorders considered previously.
The strongest predictors of TMD onset, based on the OPPERA
study, are psychological. Increased risk of TMD onset was associated
with higher baseline levels of reported somatic symptoms, psychosocial
stress, and affective distress [121,122]. Further analysis of the data
suggested that a general predisposing factor underlay the above
predictors: global psychological and somatic symptom levels appear to
represent a risk factor associated with the development of TMD
symptoms. Inasmuch as the latter findings also overlap with risk
factors associated with the likelihood that TMD symptoms will
become chronic, TMD appears to represent a condition with a strong
biopsychosocial profile, a profile that suggests the potential importance
of psychological interventions integrated into a multidisciplinary
treatment plan [123].
The diagnosis of TMD has been outlined in multiple guidelines
[124,125]. As with other COFP disorders, a comprehensive history and
physical examination is paramount. Non-pharmacologic and
pharmacologic treatments have been extensively studied. In general,
patient education is the cornerstone of any treatment plan for TMD.
This includes trigger avoidance, disorder pathogenesis, positioning,
and parafunctional habit discontinuation [126]. Splinting and various
physical therapy approaches also have been investigated with variable
evidence for efficacy [127]. Pharmacologic approaches are generally
limited by the lack of well-controlled studies assessing effectiveness of a
given agent in the chronic setting. Acute treatment may include
nonsteroidal anti-inflammatory drugs (NSAIDs), skeletal muscle
relaxants (SMRs), or short term night-time benzodiazepines [128]. The
tricyclic antidepressant, amitriptyline, may be useful in the
symptomatic treatment of TMD, although large randomized, placebo-
controlled studies are not available to support that recommendation
[129].
Tension-type headache
Tension-type headache (TTH) is one of the three most prevalent
primary headache disorders (others are migraine and cluster
headache), which together represent the most common reason that
patients seek neurologic consultation [79]. Of the three, TTH is the
most common, estimated to affect up to 46% of adults annually
worldwide [130]. It is somewhat more common among women than
men, by a ratio of approximately 5:4 [130]. There are three forms of
TTH:
1) Infrequent episodic, <1 day/month;
2) Frequent episodic, >1 day/month but <15 days/month; and
3) Chronic, >15 days/month.
Typically, patients with TTH present with complaints of mild to
moderate pain (described as “tightness” or “pressure”) in a band-like
pattern extending bilaterally from the cervical to the frontalis region.
On physical examination, patients will demonstrate no neurologic
findings, although palpation generally (but not always) reveals
pericranial and/or cervical muscle tenderness. TTH patients also
demonstrate trigger points, hyper-irritable nodes with bands of skeletal
muscle fibers that can produce radiating pain, often in a pericranial
distribution, when palpated [131]. Many patients with TTH (88%) also
present with co-existing neck pain with associated myofascial
tenderness in the cervical region [132].
The two most common TTH precipitants include stress/mental
tension and fatigue/poor sleep, although precipitants also can include
weather changes, poor health, long work hours, and frequent traveling
[133]. These precipitants and recent research suggest that myofascial
sensitivity is likely to be the most common pathway to episodic
tension-type headache [134]. With chronic TTH, central sensitization
mechanisms are likely to be implicated [135]. Aside from central
sensitization, there also is a link between psychological distress and
TTH, especially chronic TTH. Among people with chronic TTH seen
at specialty clinics, rates of both mood (~ 30%) and anxiety (~ 48%)
disorders are significantly higher than rates found in the general
population, and chronic TTH patients with psychiatric comorbidities
also exhibit higher levels of disability [136].
Multiple treatment approaches can benefit patients with episodic
TTH, including pharmacotherapy, physiotherapy, psychological
therapies, and other therapies as needed (e.g., nutrition and dietetics),
alone and in combination. The choice of treatments depends upon the
factors contributing to the headache. Generally, preventive
pharmacotherapy has been the first line of treatment for episodic TTH,
except when a more aggressive approach is needed to interrupt a
headache cycle. Physical therapy for TTH is also considered a first-line
approach, especially in patients that demonstrate trigger points and
sensitivity to palpation of pericranial and cervical musculature or
postural deviations [137]. Inasmuch as lifestyle/behavioral factors can
precipitate and maintain episodes of TTH, it is not surprising that a
range of psychological interventions has been employed in TTH
treatment, including relaxation training, biofeedback (BFB) training,
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and cognitive behavioral therapy, all of which have demonstrated good
treatment effectiveness [138].
Migraine
There are two recognized forms of migraine: migraine with aura
(classic) and migraine without aura (common). Common migraine is
approximately twice as prevalent as classic migraine. Each form of
migraine also can be characterized by its frequency: episodic (EM) or
chronic (CM). Diagnostic criteria for CM include three criteria:
1) 15 or more headache days/month;
2) Of those headache days, at least 8 must meet criteria for migraine
with or without aura or respond to migraine-specific treatment; and
3) headache duration must be at least 3 months [79].
Each form of migraine is characterized by similar features:
1) Unilateral pain that typically has a pulsating quality,
2) Moderate to severe levels of pain severity,
3) Symptoms that are aggravated by routine physical activity, and
4) Nausea, photophobia, or phonophobia.
For both types of migraine, many patients (~ 60%) experience a
prodrome that precedes headache onset, although the features of the
prodrome vary greatly (e.g., hyper-/hypo-activity, depression, food
cravings, sensitivity to smells, stiff muscles). In migraine with aura,
patients also experience visual, sensory, or motor symptoms just prior
to headache onset. The most common aura is visual, involving scotoma
that surrounds a blind spot. Next most common is sensory, with one-
sided symptoms of numbness or paresthesia that affect an upper or
lower limb.
The prevalence of migraine in the U.S. is high, affecting
approximately 14% of adults annually, of which approximately 15%
have chronic migraine [139,140]. CM patients are much more likely to
experience severe impact from migraine (interference with work,
school or social activities, severe pain, fatigue, frustration, difficulty
concentrating) relative to EM patients (72.9% vs. 42.3%). Further, rates
of depression (25.2%) and anxiety (23.6%) are significantly greater for
the CM group compared to the EM group (rates were 10.0% and 8.5%,
respectively). In fact, the odds of experiencing a major depressive
disorder (MDD), anxiety disorder (AD), or combined MDD and AD
in the past year are roughly twice as high in migraineurs than in
persons without migraine [141,142]. Interestingly, the reverse
relationship also applies for the odds of a migraine disorder among
people with psychiatric disorders: among people with MDD or AD, the
odds of experiencing migraine are significantly higher than are those
for people without a psychiatric disorder. The bidirectional
relationship, of course, raises questions about whether the disorders
share a common neurophysiology.
The physiologic mechanisms of migraine remain poorly
understood. Current theories emphasize central nervous system
activity:
1) Cortical spreading depression that activates the
trigeminovascular system, triggering a wave of cortical, meningeal, and
vascular events that produce a migraine attack, and/or
2) Central sensitization of trigeminal nociceptors, associated with
inflammatory mediators, growth factors, and neuropeptides [143,144].
Given the lack of a clear understanding of migraine
pathophysiology, it is not surprising that a range of pharmacological
and multidisciplinary approaches have been used. As it is beyond the
scope of this review to detail the various pharmacological therapies
that have proved effective for acute treatment and optimal care, the
interested reader is directed to Canadian practice guidelines developed
recently [145]. Similarly, for information regarding effective
multidisciplinary approaches to episodic and chronic migraine, the
interested reader is directed to research that has examined the effects
of medical and behavioral treatment, alone and in combination [146].
Cluster headache
Cluster headache (CH) is typified by recurrent episodes of unilateral
pain, usually involving the orbital or periorbital region that is
innervated by the ophthalmic division of the trigeminal nerve.
Common descriptions of CH pain are sharp, piercing, burning, and
pulsating. Onset tends to be rapid, with an attack increasing from
discomfort to excruciating pain in a span of minutes, and the duration
of excruciating pain lasting until the headache ends, often quite
suddenly [147]. Aside from severe unilateral headache, over 80% of
CH patients present with same-sided unilateral lacrimation, nasal
congestion, and/or rhinorrhea, and over 40% describe photophobia or
phonophobia [148]. Patients often demonstrate agitation and
restlessness during an attack, such as pacing, rocking back and forth,
or banging a head against a wall [149]. Cluster headaches are not
common, as epidemiologic studies estimate a lifetime prevalence of
0.12%, and are more common in men than women with a ratio of 2.5:1
[150,151].
The term, cluster headache, derives from the clinical presentation of
frequent headache attacks that cluster together into bouts. To qualify as
CH, headaches should occur at least five times per bout; each bout can
last several weeks. Often, patients experience far more than five
headaches in a cluster [152]. Most patients present with one bout per
year with a mean duration of about two months per bout [147].
Almost three out of every four patients report recurrent attacks during
the night that awaken them from sleep [152].
CH is considered to be one of a group of trigeminal autonomic
cephalalgias [79]. Both peripheral and central factors are thought to
play a part. Peripheral involvement is associated with
trigeminovascular innervation of the ophthalmic and middle cerebral
arteries, both of which have demonstrated local vasodilatation during
attacks [153]. Central factors are implicated by features that suggest
that the attacks may be occasioned by serotonergic dysfunction and/or
hypothalamic discharge [143,154].
Not surprisingly, rates of depression and anxiety disorders are high
in CH patients: one study reported that 43.0% reported clinically
significant levels of depression, and 75.7% reported clinically
significant anxiety [155]. Unlike migraine, where a bidirectional
relationship appears to exist between headache and psychological
distress, the relationship in CH appears to go in only one direction-CH
appears to occasion psychological distress [156,157].
Despite the unique characteristics of CH that should aid differential
diagnosis when a careful history is taken, the data consistently show a
substantial lag between the onset of CH symptoms and its accurate
diagnosis that can exceed 5 years [148]. Common misdiagnoses
included migraine, trigeminal neuralgia, and sinusitis [158]. For
patients who are correctly diagnosed, all guidelines point to the
importance of patient education in order to diminish the emotional
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anguish that can be associated with recurrent bouts [148,158]. Several
trials have shown benefit from administration of high-dose, high-flow-
rate, and normobaric oxygen therapies, and others show benefit from
intranasal and subcutaneous sumatriptan and oral and intranasal
zolmitriptan [159,160]. Sumatriptan in an oral form also has been used
for long-term reduction of CH attacks, although verapamil has
emerged as the drug of choice for preventive care [160].
Summary and Recommendations
While BMS and other idiopathic and neuropathic COFP disorders
may not singly be common in the general population, collectively, their
prevalence supports the need for a general understanding by the
generalist health provider and a thorough understanding by the
neurologist or oral health professional. These disorders should be
considered especially carefully for older adults, as their prevalence
escalates with advancing age. Further, several of the disorders
described previously are diagnoses of exclusion, requiring a careful
history and physical examination, secondary to the lack of definitive
diagnostic tests that can be adduced to reach a high level of confidence
(“probable” or “possible” are most likely). Because of the diverse
symptom profiles that these disorders can present, patients with
idiopathic/neuropathic COFP are likely to appear for treatment to a
broad range of providers.
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